Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer.

Next Previous
Trial Profile

Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jun 2010 Planned end date changed from 1 Feb 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
  • 12 Mar 2009 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov.
  • 15 May 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top